These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 26895345)

  • 21. Liquid-based cervical cytology and microbiological analyses in women using cooper intrauterine device and levonorgestrel-releasing intrauterine system.
    Eleuterio J; Giraldo PC; Silveira Gonçalves AK; Nunes Eleuterio RM
    Eur J Obstet Gynecol Reprod Biol; 2020 Dec; 255():20-24. PubMed ID: 33065517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
    Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The levonorgestrel intrauterine system: cohort study to assess satisfaction in a postpartum population in Kenya.
    Hubacher D; Masaba R; Manduku CK; Chen M; Veena V
    Contraception; 2015 Apr; 91(4):295-300. PubMed ID: 25601351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selection and performance of the levonorgestrel-releasing intrauterine system.
    Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
    Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): data from an international survey.
    Römer T; Linsberger D
    Eur J Contracept Reprod Health Care; 2009 Dec; 14(6):391-8. PubMed ID: 19929641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey of young women's perceptions of the influence of the Levonorgestrel-Intrauterine System or copper-intrauterine device on sexual desire.
    Malmborg A; Brynhildsen J; Hammar M
    Sex Reprod Healthc; 2019 Oct; 21():75-80. PubMed ID: 31395237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
    Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
    Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
    Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Van Vliet H; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Helmerhorst F; Guillebaud J
    Cochrane Database Syst Rev; 2004; 2004(3):CD001776. PubMed ID: 15266453
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acceptability of an experimental intracervical device: results of a study controlling for selection bias.
    Shain RN; Ratsula K; Toivonen J; Lähteenmäki P; Luukkainen T; Holden AE; Rosenthal M
    Contraception; 1989 Jan; 39(1):73-84. PubMed ID: 2491982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.
    Spotnitz ME; Natarajan K; Ryan PB; Westhoff CL
    Obstet Gynecol; 2020 Feb; 135(2):319-327. PubMed ID: 31923062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised clinical trial to assess satisfaction with the levonorgestrel- releasing intrauterine system inserted at caesarean section compared to postpartum placement.
    Braniff K; Gomez E; Muller R
    Aust N Z J Obstet Gynaecol; 2015 Jun; 55(3):279-83. PubMed ID: 26053465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a levonorgestrel intrauterine system versus a copper intrauterine device on menstrual changes and uterine artery Doppler.
    Rezk M; Elshamy E; Shaheen AE; Shawky M; Marawan H
    Int J Gynaecol Obstet; 2019 Apr; 145(1):18-22. PubMed ID: 30706471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Female sexual function in women using LARC methods.
    Trigo ACM; Maron CC; Pinheiro MSA; da Silva SBL; Brito MB
    Gynecol Endocrinol; 2022 Jan; 38(1):68-72. PubMed ID: 34672861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg versus other long-acting reversible contraceptives for contraception in Spain.
    Conde JCQ; Parra Ribes I; Perelló-Capo J; Lobo Abascal P; García IC; Andeyro García M; Gutiérrez Alés J; Herrero Conde M; Rius Tarruella J; Espinós Lafuente B
    Eur J Contracept Reprod Health Care; 2024 Oct; 29(5):224-232. PubMed ID: 38989683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in body composition in women using long-acting reversible contraception.
    Silva Dos Santos PN; Madden T; Omvig K; Peipert JF
    Contraception; 2017 Apr; 95(4):382-389. PubMed ID: 28041992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible contraceptives as effective methods of preventing pregnancy.
    French R; Cowan F; Mansour D; Morris S; Hughes D; Robinson A; Proctor T; Summerbell C; Logan S; Guillebaud J
    Cochrane Database Syst Rev; 2001; (2):CD001776. PubMed ID: 11406007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.